Our mission at MSK has always been to care for and cure people with cancer. As part of this goal, we’ve worked for decades to find new treatments. Many of our innovations and approaches have set the standard for care.
The MSK Lymphoma Service has one of the largest and most innovative clinical trial programs in the world. We offer a diverse range of treatment options for patients with Hodgkin and non-Hodgkin lymphoma. Because of our active clinical trial research program, we have helped to develop most of the lymphoma drugs that have improved patient outcomes and are currently FDA approved. Many of our clinical trials turn the latest discoveries from the laboratory into new treatments for patients with lymphoma.
Choosing MSK may give you access to new treatment options that are not yet readily available and could turn out to be tomorrow’s cures. We have extensive experience in matching patients with the clinical trials that will benefit them the most.
Burkitt’s Lymphoma
Newly Diagnosed/Frontline Studies and Advanced Disease
A Phase 1B Study of ELA026 in People with Secondary Hemophagocytic Lymphohistiocytosis
William Johnson
[Protocol 23-366]
Prior Treatment (Relapsed/Refractory)
A Phase 2 Study of Nanatinostat and Valganciclovir in People With Lymphoma
Zachary Epstein-Peterson
[Protocol 23-115]
A Phase 1B Study of ELA026 in People with Secondary Hemophagocytic Lymphohistiocytosis
William Johnson
[Protocol 23-366]
A Phase 1 Study of BMS-986458 Alone and With Rituximab in People With Non-Hodgkin Lymphoma
Jennifer K. Lue
[Protocol 24-050]
Chronic Lymphocytic Lymphoma (CLL)
Newly Diagnosed/Frontline Studies and Advanced Disease
A Phase II Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Leukemia
Andrew D. Zelenetz
[Protocol 18-427]
A Phase 1B Study of ELA026 in People with Secondary Hemophagocytic Lymphohistiocytosis
William Johnson
[Protocol 23-366]
Prior Treatment (Relapsed/Refractory)
A Phase I Study of BGB-11417 in People with Recurrent or Persistent B-Cell Non-Hodgkin Lymphoma
Andrew D. Zelenetz
[Protocol 21-187]
A Phase 2 Study of Venetoclax, Obinutuzumab, and Acalabrutinib to Treat Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Andrew D. Zelenetz
[Protocol 22-359]
A Phase 1 Study of ABBV-319 in People With B-Cell Cancers
Paola Ghione
[Protocol 23-255]
A Phase 1B Study of ELA026 in People with Secondary Hemophagocytic Lymphohistiocytosis
William Johnson
[Protocol 23-366]
A Phase 1 Study of BMS-986458 Alone and With Rituximab in People With Non-Hodgkin Lymphoma
Jennifer K. Lue
[Protocol 24-050]
Diffuse Large B-Cell Lymphoma
Newly Diagnosed/Frontline Studies and Advanced Disease
A Phase II/III Study of CC-486 (Oral Azacitidine) plus Standard Therapy in Older Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma
Colette N. Owens
[Protocol 21-210]
A Phase 1B Study of ELA026 in People with Secondary Hemophagocytic Lymphohistiocytosis
William Johnson
[Protocol 23-366]
Prior Treatment (Relapsed/Refractory)
A Phase I/II Study of CFT7455 in People with Non-Hodgkin Lymphoma or Multiple Myeloma
Steven M. Horwitz
[Protocol 21-301]
A Phase 2 Study of Nanatinostat and Valganciclovir in People With Lymphoma
Zachary Epstein-Peterson
[Protocol 23-115]
A Phase 2 Study of Belantamab Mafodotin in People With Lymphoma
Andrew D. Zelenetz
[Protocol 23-322]
A Phase 1/2 Study of IPH6501, a Novel Immunotherapy, in People With Non-Hodgkin Lymphoma
Lorenzo Falchi
[Protocol 23-340]
A Phase 1B Study of ELA026 in People with Secondary Hemophagocytic Lymphohistiocytosis
William Johnson
[Protocol 23-366]
A Phase 1 Study of BMS-986458 Alone and With Rituximab in People With Non-Hodgkin Lymphoma
Jennifer K. Lue
[Protocol 24-050]
Follicular Lymphoma
Newly Diagnosed/Frontline Studies and Advanced Disease
A Phase II/III Study of CC-486 (Oral Azacitidine) plus Standard Therapy in Older Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma
Colette N. Owens
[Protocol 21-210]
A Phase II Study of Mosunetuzumab as Initial Chemotherapy-Free Treatment for Follicular Lymphoma
Lorenzo Falchi
[Protocol 22-100]
A Phase 1B Study of ELA026 in People with Secondary Hemophagocytic Lymphohistiocytosis
William Johnson
[Protocol 23-366]
Prior Treatment (Relapsed/Refractory)
A Phase IB/III Study of Lenalidomide and Rituximab plus Tazemetostat or Placebo in Patients with Recurrent or Persistent Follicular Lymphoma
Gilles Salles
[Protocol 20-252]
A Phase I/II Study of CFT7455 in People with Non-Hodgkin Lymphoma or Multiple Myeloma
Steven M. Horwitz
[Protocol 21-301]
A Phase 1 Study of ABBV-319 in People With B-Cell Cancers
Paola Ghione
[Protocol 23-255]
A Phase 1/2 Study of IPH6501, a Novel Immunotherapy, in People With Non-Hodgkin Lymphoma
Lorenzo Falchi
[Protocol 23-340]
A Phase 3 Study of Epcoritamab Plus Standard Treatment Compared to Standard Treatment Alone in People With Follicular Lymphoma
Lorenzo Falchi
[Protocol 23-355]
A Phase 1B Study of ELA026 in People with Secondary Hemophagocytic Lymphohistiocytosis
William Johnson
[Protocol 23-366]
A Phase 1 Study of BMS-986458 Alone and With Rituximab in People With Non-Hodgkin Lymphoma
Jennifer K. Lue
[Protocol 24-050]
HIV+ Lymphoma
Newly Diagnosed/Frontline Studies and Advanced Disease
AIDS Malignancy Consortium 101: A Pilot Study to Assess Adding Ibrutinib to Standard R-EPOCH Treatment for AIDS-Related Lymphomas
Ariela Noy
[Protocol 17-543]
A Phase 1B Study of ELA026 in People with Secondary Hemophagocytic Lymphohistiocytosis
William Johnson
[Protocol 23-366]
Prior Treatment (Relapsed/Refractory)
A Phase I Study of Nivolumab and Ipilimumab Immunotherapy for Advanced HIV-Related Solid Tumors, including Hodgkin Lymphoma
Mark A. Dickson
[Protocol 16-1286]
A Phase 2 Study of Nanatinostat and Valganciclovir in People With Lymphoma
Zachary Epstein-Peterson
[Protocol 23-115]
A Phase 1B Study of ELA026 in People with Secondary Hemophagocytic Lymphohistiocytosis
William Johnson
[Protocol 23-366]
Hodgkin Lymphoma
Newly Diagnosed/Frontline Studies and Advanced Disease
A Phase 1B Study of ELA026 in People with Secondary Hemophagocytic Lymphohistiocytosis
William Johnson
[Protocol 23-366]
A Phase 2 Study Comparing Rituximab and Mosunetuzumab Immunotherapy in People with Nodular Lymphocyte-Predominant Hodgkin Lymphoma
Raphael Steiner
[Protocol 23-381]
A Phase 2 Study of BV-AVD in People With Newly Diagnosed Bulky Hodgkin Lymphoma
Robert Stuver
[Protocol 24-039]
Prior Treatment (Relapsed/Refractory)
A Phase II Study of Pembrolizumab Immunotherapy plus Involved Site Radiation Therapy to Treat Early Recurrent or Persistent Hodgkin Lymphoma
Alison J. Moskowitz
[Protocol 17-054]
A Phase I Study of KT-333 in People with Lymphoma and Large Granular Lymphocytic Leukemia
Zachary Epstein-Peterson
[Protocol 22-348]
A Phase 2 Study of Nanatinostat and Valganciclovir in People With Lymphoma
Zachary Epstein-Peterson
[Protocol 23-115]
A Phase 1B Study of ELA026 in People with Secondary Hemophagocytic Lymphohistiocytosis
William Johnson
[Protocol 23-366]
A Phase 2 Study Comparing Rituximab and Mosunetuzumab Immunotherapy in People with Nodular Lymphocyte-Predominant Hodgkin Lymphoma
Raphael Steiner
[Protocol 23-381]
Mantle Cell Lymphoma
Newly Diagnosed/Frontline Studies and Advanced Disease
A Phase II Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Leukemia
Andrew D. Zelenetz
[Protocol 18-427]
A Phase 1B Study of ELA026 in People with Secondary Hemophagocytic Lymphohistiocytosis
William Johnson
[Protocol 23-366]
Prior Treatment (Relapsed/Refractory)
A Phase I Study of BGB-11417 in People with Recurrent or Persistent B-Cell Non-Hodgkin Lymphoma
Andrew D. Zelenetz
[Protocol 21-187]
A Phase I/II Study of CFT7455 in People with Non-Hodgkin Lymphoma or Multiple Myeloma
Steven M. Horwitz
[Protocol 21-301]
A Phase 1 Study of ABBV-319 in People With B-Cell Cancers
Paola Ghione
[Protocol 23-255]
A Pilot Study of Glofitamab and Lenalidomide in People With Previously Treated Mantle Cell Lymphoma
Anita Kumar
[Protocol 23-319]
A Phase 1/2 Study of IPH6501, a Novel Immunotherapy, in People With Non-Hodgkin Lymphoma
Lorenzo Falchi
[Protocol 23-340]
A Phase 1B Study of ELA026 in People with Secondary Hemophagocytic Lymphohistiocytosis
William Johnson
[Protocol 23-366]
A Phase 1 Study of BMS-986458 Alone and With Rituximab in People With Non-Hodgkin Lymphoma
Jennifer K. Lue
[Protocol 24-050]
Marginal Zone Lymphoma
Newly Diagnosed/Frontline Studies and Advanced Disease
A Phase 1B Study of ELA026 in People with Secondary Hemophagocytic Lymphohistiocytosis
William Johnson
[Protocol 23-366]
Prior Treatment (Relapsed/Refractory)
A Phase 1 Study of ABBV-319 in People With B-Cell Cancers
Paola Ghione
[Protocol 23-255]
A Phase 1B Study of ELA026 in People with Secondary Hemophagocytic Lymphohistiocytosis
William Johnson
[Protocol 23-366]
A Phase 1 Study of BMS-986458 Alone and With Rituximab in People With Non-Hodgkin Lymphoma
Jennifer K. Lue
[Protocol 24-050]
Mediastinal Grey Zone Lymphoma
Newly Diagnosed/Frontline Studies and Advanced Disease
A Phase 1B Study of ELA026 in People with Secondary Hemophagocytic Lymphohistiocytosis
William Johnson
[Protocol 23-366]
Prior Treatment (Relapsed/Refractory)
A Phase 1B Study of ELA026 in People with Secondary Hemophagocytic Lymphohistiocytosis
William Johnson
[Protocol 23-366]
A Phase 1 Study of BMS-986458 Alone and With Rituximab in People With Non-Hodgkin Lymphoma
Jennifer K. Lue
[Protocol 24-050]
Small Lymphocytic Lymphoma (SLL)
Newly Diagnosed/Frontline Studies and Advanced Disease
A Phase II Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Leukemia
Andrew D. Zelenetz
[Protocol 18-427]
A Phase 1B Study of ELA026 in People with Secondary Hemophagocytic Lymphohistiocytosis
William Johnson
[Protocol 23-366]
Prior Treatment (Relapsed/Refractory)
A Phase I Study of BGB-11417 in People with Recurrent or Persistent B-Cell Non-Hodgkin Lymphoma
Andrew D. Zelenetz
[Protocol 21-187]
A Phase 1 Study of ABBV-319 in People With B-Cell Cancers
Paola Ghione
[Protocol 23-255]
A Phase 1B Study of ELA026 in People with Secondary Hemophagocytic Lymphohistiocytosis
William Johnson
[Protocol 23-366]
A Phase 1 Study of BMS-986458 Alone and With Rituximab in People With Non-Hodgkin Lymphoma
Jennifer K. Lue
[Protocol 24-050]
Peripheral T-cell Lymphoma
Newly Diagnosed/Frontline Studies and Advanced Disease
A Phase II Study Assessing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma
Alison J. Moskowitz
[Protocol 21-343]
A Phase 1B Study of ELA026 in People with Secondary Hemophagocytic Lymphohistiocytosis
William Johnson
[Protocol 23-366]
Prior Treatment (Relapsed/Refractory)
A Phase I Study Assessing the Addition of Lenalidomide to the Usual Combination Chemotherapy for HTLV-Associated Adult T-Cell Leukemia-Lymphoma
Steven M. Horwitz
[Protocol 21-140]
A Phase I/II Study of CFT7455 in People with Non-Hodgkin Lymphoma or Multiple Myeloma
Steven M. Horwitz
[Protocol 21-301]
A Phase I Study of ONO-4685 Immunotherapy in People with T-Cell Lymphoma
William Johnson
[Protocol 22-045]
A Phase 2 Study of Nanatinostat and Valganciclovir in People With Lymphoma
Zachary Epstein-Peterson
[Protocol 23-115]
A Phase 2 Study of Ruxolitinib in People With T-Cell Large Granular Lymphocytic Leukemia
Alison J. Moskowitz
[Protocol 23-280]
A Phase 1B Study of ELA026 in People with Secondary Hemophagocytic Lymphohistiocytosis
William Johnson
[Protocol 23-366]
A Phase 1 Study of BMS-986458 Alone and With Rituximab in People With Non-Hodgkin Lymphoma
Jennifer K. Lue
[Protocol 24-050]
Cutaneous T-cell Lymphoma
Newly Diagnosed/Frontline Studies and Advanced Disease
A Phase 1B Study of ELA026 in People with Secondary Hemophagocytic Lymphohistiocytosis
William Johnson
[Protocol 23-366]
Prior Treatment (Relapsed/Refractory)
A Phase II Study of Ruxolitinib in Patients with Persistent or Recurrent T-Cell or NK-Cell Lymphoma
Alison J. Moskowitz
[Protocol 16-1542]
A Phase II Study to Determine the Optimal Dose of Brentuximab Vedotin for Mycosis Fungoides and Lymphomatoid Papulosis
Alison J. Moskowitz
[Protocol 18-147]
A Phase II Study of Pembrolizumab Immunotherapy plus Gemcitabine to Treat Advanced Mycosis Fungoides or Sézary Syndrome
Alison J. Moskowitz
[Protocol 21-242]
A Phase I Study of ONO-4685 Immunotherapy in People with T-Cell Lymphoma
William Johnson
[Protocol 22-045]
A Phase 1B Study of ELA026 in People with Secondary Hemophagocytic Lymphohistiocytosis
William Johnson
[Protocol 23-366]
A Phase 1 Study of BMS-986458 Alone and With Rituximab in People With Non-Hodgkin Lymphoma
Jennifer K. Lue
[Protocol 24-050]
NK T-cell Lymphoma
Newly Diagnosed/Frontline Studies and Advanced Disease
A Phase 1B Study of ELA026 in People with Secondary Hemophagocytic Lymphohistiocytosis
William Johnson
[Protocol 23-366]
Prior Treatment (Relapsed/Refractory)
A Phase I Study Assessing the Addition of Lenalidomide to the Usual Combination Chemotherapy for HTLV-Associated Adult T-Cell Leukemia-Lymphoma
Steven M. Horwitz
[Protocol 21-140]
A Phase 2 Study of Nanatinostat and Valganciclovir in People With Lymphoma
Zachary Epstein-Peterson
[Protocol 23-115]
A Phase 1B Study of ELA026 in People with Secondary Hemophagocytic Lymphohistiocytosis
William Johnson
[Protocol 23-366]
A Phase 1 Study of BMS-986458 Alone and With Rituximab in People With Non-Hodgkin Lymphoma
Jennifer K. Lue
[Protocol 24-050]
Waldenstrom’s Macroglobulinemia
Newly Diagnosed/Frontline Studies and Advanced Disease
A Phase II Study Assessing Venetoclax Added to Ibrutinib and Rituximab for Waldenström's Macroglobulinemia/Lymphoplasmacytic Lymphoma
M. Lia Palomba
[Protocol 21-336]
A Phase 1B Study of ELA026 in People with Secondary Hemophagocytic Lymphohistiocytosis
William Johnson
[Protocol 23-366]
Prior Treatment (Relapsed/Refractory)
A Phase 1 Study of ABBV-319 in People With B-Cell Cancers
Paola Ghione
[Protocol 23-255]
A Phase 1B Study of ELA026 in People with Secondary Hemophagocytic Lymphohistiocytosis
William Johnson
[Protocol 23-366]
A Phase 1 Study of BMS-986458 Alone and With Rituximab in People With Non-Hodgkin Lymphoma
Jennifer K. Lue
[Protocol 24-050]
A Phase 2 Study of BGB-11417 in People With Waldenström's Macroglobulinemia
M. Lia Palomba
[Protocol 24-067]
Request an Appointment
We’re available 24 hours a day, 7 days a week
